Foresee Pharmaceuticals Co., Ltd. (TPEX:6576)

Market Cap	13.31B
Revenue (ttm)	346.56M
Net Income (ttm)	-930.72M
Shares Out	154.78M
EPS (ttm)	-6.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	337,886
Average Volume	231,031
Open	84.60
Previous Close	84.60
Day's Range	84.50 - 86.80
52-Week Range	68.40 - 107.50
Beta	1.17
RSI	79.55
Earnings Date	Feb 24, 2025

About Foresee Pharmaceuticals

Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company’s stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6576

Financial Performance

In 2023, Foresee Pharmaceuticals's revenue was 195.04 million, a decrease of -35.31% compared to the previous year's 301.51 million. Losses were -1.04 billion, 119.3% more than in 2022.